IRadimed Corporation

NASDAQ:IRMD

Medical - Devices

Healthcare
$82.31 +0.73%

+$0.67 today

Market cap
$1.05B
Beta
0.92
P/E (TTM)
49.7
EPS (TTM)
$1.85
Dividend yield
1.35%
52W Low $55.11High $107.90

Volume 0.08M

Average 0.12M

IRMD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

IRadimed CorporationNASDAQ: IRMD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $2.61M (cash outflow) rose 14.4% year over year, behind the +109.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 76.0% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.

Context

  • Financing cash flow amounted to 21.0% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Financing cash flow grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.4% toward the trailing-twelve-month pace of +109.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.61M-76.0% QoQ
Last fiscal yearDec 2025
-$17.6M+22.8% YoY
LTMMar 2026
-$17.93M+109.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year+22.8%——
3-year CAGR+11.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(17.6M) USD
Year-over-year change
-22.8%

Financing Cash Flow vs competitors

How IRMD compares with its peers on the latest reported figures

  • IRMD's LTM Mar 2026 financing cash flow of $17.93M is the 9th largest of the 11 companies compared; the peer median is $20.11M.
  • Its year-over-year change of +109.1% is the 4th highest of 11, against a peer median of +3.6%.
  • Financing cash flow amounts to 20.8% of revenue for IRMD, versus a peer median of 17.4%.
IRMD Competitors Peer median
Financing Cash Flow for IRMD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AXGNAxoGen, Inc.LTM Sep 2026$293.55M +4152.5%+80.2%110.0%
TNDMTandem Diabetes Care, Inc.LTM Mar 2026$235.48M +2476.9%—22.9%
AHCOAdaptHealth Corp.LTM Apr 2026$193.59M -34.7%+66.0%6.8%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$145.87M -48.2%+24.9%18.5%
OPKOPKO Health, Inc.LTM Mar 2026$119.19M -174.7%—20.5%
INMDInMode Ltd.LTM Mar 2026$66.66M -82.6%+45.3%17.8%
CRONCronos Group Inc.LTM Mar 2026$35.11M +898.6%+91.2%17.1%
CTEVClaritev CorporationLTM Mar 2026$28.15M -56.0%—2.9%
IRMDIRadimed CorporationLTM Mar 2026$17.93M +109.1%+11.5%20.8%
MDXGMiMedx Group, Inc.LTM Mar 2026$5.12M +41.8%+110.5%1.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$1.26M +101.5%—0.1%
Peer median (excluding IRMD) $20.11M+3.6%+73.1%17.4%

Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income9.33M12.83M17.19M19.23M22.48M
Depreciation & Amortization1.41M670.67K765.18K817.66K1.17M
Deferred Income Tax523.61K57.1K(1.17M)(697.65K)0
Stock-Based Compensation1.46M1.39M2.19M2.52M2.92M
Change in Working Capital(1.58M)(5.06M)(5.91M)3.75M(4.35M)
Accounts Receivables(575.54K)(8.24M)841.91K1.76M(3.03M)
Inventory(393.32K)(1.31M)(7.47M)3.13M(1.38M)
Accounts Payables30.41K1.12M(216.44K)(861.62K)(76K)
Other Working Capital(637.72K)3.37M932.43K(277.58K)135K
Other Non-Cash Items119.04K148.74K402.32K(3.02K)2.73M
Operating Cash Flow11.26M10.04M13.47M25.62M24.95M
Capital Expenditures(741.76K)(1.87M)(8.01M)(8.01M)(7.77M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments1.39M500K000
Other Investing Activities(259.43K)(1.05M)(566.66K)(811.75K)(656K)
Investing Cash Flow648.24K(1.37M)(8.01M)(8.82M)(8.42M)
Debt Repayment00000
Common Stock Issued00029.62K0
Common Stock Repurchased00000
Dividends Paid0(12.56M)(13.22M)(13.68M)(15.04M)
Other Financing Activities24.43K(147.27K)(433.6K)(688.16K)(2.56M)
Financing Cash Flow24.43K(12.71M)(13.66M)(14.34M)(17.6M)
Effect of Forex Changes00000
Net Change in Cash11.93M(4.04M)(8.2M)2.47M(1.08M)
Free Cash Flow10.52M8.17M5.46M17.62M17.18M

IRadimed Corporation

NASDAQ:IRMD

Intrinsic Alpha fair value

Locked

Current Price

$82.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.